E-mail a Wiley Online Library Link

Chi Young Ok, Zijun Y. Xu-Monette, Alexandar Tzankov, Dennis P. O'Malley, Santiago Montes-Moreno, Carlo Visco, Michael B. Møller, Karen Dybkær, Attilio Orazi, Youli Zu, Govind Bhagat, Kristy L. Richards, Eric D. Hsi, J. Han van Krieken, Maurilio Ponzoni, John P. Farnen, Miguel A. Piris, Jane N. Winter, L. Jeffrey Medeiros and Ken H. Young Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: A report from the International DLBCL Rituximab-CHOP Consortium Program Cancer 120

Version of Record online: 19 MAR 2014 | DOI: 10.1002/cncr.28664

Compared with patients who have cyclin D1-negative diffuse large B-cell lymphoma (DLBCL), men are more commonly affected with cyclin D1-positive DLBCL and are significantly younger. There are no other significant differences in clinical presentation, pathologic features, overall survival, or progression-free survival between these 2 subgroups of patients with DLBCL; however, recognition of such subtypes is critical in the differential diagnosis of lymphoma.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field